Tosufloxacin p-Toluenesulfonate Hydrate
Tosufloxacin p-Toluenesulfonate Hydrate Basic information
- Product Name:
- Tosufloxacin p-Toluenesulfonate Hydrate
- Synonyms:
-
- Tosufloxacin (tosylate hydrate)
- Tosufloxacin p-Toluenesulfonate Hydrate
- 1,8-Naphthyridine-3-carboxylic acid, 7-(3-amino-1-pyrrolidinyl)-1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-4-oxo-, 4-methylbenzenesulfonate, hydrate (1:1:)
- A-61827 tosylate hydrate
- T-3262 Tosylate Hydrate
- Tosufloxacin tosylate hydrate (T3262, A61827)
- Tosufloxacin tosylate hydrate, 10 mM in DMSO
- Tosufloxacin toluenesulfonate hydrate - Bio-X ?
- CAS:
- 1400591-39-0
- MF:
- C26H23F3N4O6S
- MW:
- 576.55
- Mol File:
- 1400591-39-0.mol
Tosufloxacin p-Toluenesulfonate Hydrate Chemical Properties
- storage temp.
- Store at -20°C
- solubility
- DMSO : ≥ 33 mg/mL (55.50 mM)
- form
- Solid
- color
- White to off-white
Tosufloxacin p-Toluenesulfonate Hydrate Usage And Synthesis
Uses
Tosufloxacin tosylate hydrate (A-61827) is an orally active fluoroquinolone antibiotic. Tosufloxacin shows a broad spectrum of antibacterial activity against gram-positive and gram-negative bacteria[1][2].
Definition
ChEBI: A racemate comprising equimolar amounts of (R)- and (S)-tosufloxacin tosylate hydrate.
in vivo
Tosufloxacin tosylate hydrate (T-3262) (oral gavage; 0.16-13.39 mg/kg; once) treatment shows antibacterial activity against S. aureus, E. coli, and P. aeruginosa in vivo[2].
| Animal Model: | Male Slc:ICR mice infected with S. aureus[2] |
| Dosage: | 1.27-2.15 mg/kg |
| Administration: | Oral gavage; 1.27-2.15 mg/kg; once |
| Result: | Showed 50% effective dose (ED50) of 1.62 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.0125 μg/mL. |
| Animal Model: | Male Slc:ICR mice infected with E. coli[2] |
| Dosage: | 0.16-0.30 mg/kg |
| Administration: | Oral gavage; 0.16-0.30 mg/kg; once |
| Result: | Showed 50% effective dose (ED50) of 0.22 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.0125 μg/mL. |
| Animal Model: | Male Slc:ICR mice infected with P. aeruginosa[2] |
| Dosage: | 7.66-13.39 mg/kg |
| Administration: | Oral gavage; 7.66-13.39 mg/kg; once |
| Result: | Showed 50% effective dose (ED50) of 10.13 mg/kg (body weight) at 7 days after infection. Showed MIC value of 0.78 μg/mL. |
IC 50
Quinolone
References
[1] Chu DT, et al. Synthesis and biological properties of A-71497: a prodrug of tosufloxacin. Drugs Exp Clin Res. 1990;16(9):435-43. PMID:2100244
[2] Fujimaki K, et al. In vitro and in vivo antibacterial activities of T-3262, a new fluoroquinolone. Antimicrob Agents Chemother. 1988 Jun;32(6):827-33. DOI:10.1128/AAC.32.6.827
Tosufloxacin p-Toluenesulfonate HydrateSupplier
- Tel
- 18210857532; 18210857532
- jkinfo@jkchemical.com
- Tel
- 021-58955995
- sales@medchemexpress.cn
- Tel
- 022-6537-8550 15522853686
- sales@altasci.com.cn
- Tel
- 021-61312847; 18021002903
- 3008007409@qq.com
- Tel
- 010-50973130 18101056239
- 3193328036@qq.com